Innovation In The Prefilled Syringe Industry - Biologics And Autoinjection Devices Shaping Future R&D Trends


GBI Research, the leading business intelligence provider, has released its latest research, Innovation in the Prefilled Syringe Market Biologics and Autoinjection Devices Shaping Future R&D Trends, which provides insights into possible future avenues of R&D in the prefilled syringe market. This includes an overview of problems and possible solutions, as well as discussion of how the devices have developed to date to address problems with contamination, safety, fragility and ease of use.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.
    
 
The market for prefilled syringes is being driven by the rise in popularity of autoinjection devices for the home-use market. As health authorities seek to reduce costs, facilitating patients in self-administering their medication is one major way of reducing the strain on resources for providers. Additionally, patients prefer this option as it does not require them to travel to hospital and can be accommodated in their own home.
 
Innovation is also being driven by safety. This area has seen increasing innovation in response to regulations and guidelines concerning needlestick injury. This is an area of rising concern as the number of logged needlestick injuries in healthcare workers is high and thought to be considerably under-reported. Measures to ensure healthcare provider safety have been put in place, and pharmaceutical companies are responding by improving the safety of their prefilled syringes in order to increase their appeal and gain market share. Safety devices have moved from active devices, which require activation by the user, to passive, which are automatically activated. The next steps are being made in integrating the safety device into the needle during manufacture.
 

The development of injectable biologic therapies is a major factor in the future prospects of prefilled syringes. Although oral biologics are something that companies are aiming for and there are some in development, many peptides are broken down too quickly in the stomach and are therefore not useful in treatment. The mainstay of biologic treatment is likely to remain injectable, whether intravenous, subcutaneous or intramuscular, for the foreseeable future. As such, companies need to overcome the limitations of prefilled syringes in order to provide convenient method of administration and win market share.
 
Scope
  • An overview of issues in the market.
  • Innovative solutions to these problems.
  • Future developments expected in the market by leading players
Reasons to buy
  • Understand how the prefilled syringe market has adapted to issues.
  • Predict which innovations are likely to be most successful in the future.
  • Gain an understanding of areas of unmet need in the market
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Figures 5

2 Innovation in Prefilled Syringes - Overview 6
2.1 Overview 6
 
3 Innovation in Prefilled Syringes - Introduction 7
3.1 What are Prefilled Syringes? 7
3.2 The Current Position of Prefilled Syringes in the Pharmaceutical Market 7
3.3 Factors Fueling Growth of Prefilled Syringes 7
3.4 Issues around the Use of Prefilled Syringes 8
3.5 Where Does Innovation Lie? 8
4 Innovation in Prefilled Syringes - Current Device Technologies and Associated Drivers and Barriers 9
4.1 Glass Syringes versus Plastic Syringes 9
4.1.1 Fragility 9
4.1.2 Dimensional Variability 9
4.1.3 Siliconization 9
4.1.4 Delamination 10
4.1.5 Tungsten Contamination 10
4.2 Autoinjection Devices 11
4.3 Safety Devices on Prefilled Syringes 11
4.4 Prefilled Diluent Syringes 12
4.5 Biologics Driving Innovation in Prefilled Syringes 12

5 Innovation in Prefilled Syringes - Formulation Considerations and Challenges for Pharmaceutical Companies 13
5.1 Drug Viscosity 13
5.2 Extractables and Leachables 13
5.3 Lyophilized Drugs versus Liquid-stable Formulations 14
6 Innovations in Prefilled Syringes - Overcoming Current Barriers and Trends in Development 15
6.1 Innovative Ways of Gaining Life Cycle Extensions for Existing Products 15
6.2 Plastic Syringes Offer Some Improvements over Traditional Glass Syringes 16
6.2.1 Polypropylene 16
6.2.2 Cyclo-olefin Polymers and Co-polymers 16
6.3 Extractables and Leachables 18
6.3.1 Glass Coatings - Reducing Silicone and Silicone Baking 18
6.3.2 Coated Stoppers 18
6.4 Safety Innovations 19
6.5 Integrated Needles - Advancements on the Luer Lock System 20
6.6 Filling Technologies and Removing the Air Bubble 20
6.7 Needle Length - Reducing Length can Increase Accuracy of Subcutaneous Injections 20
6.8 Manufacturing Advances - Sterilizing Syringes 21
6.8.1 Restricted Access Barrier Systems 21
6.8.2 Electron Beam Sterilization Tunnels 21
6.9 Automating and Streamlining the Manufacture of Prefilled Syringes 22
6.10 Manufacturing Flexibility and Integrated Systems 22
6.11 Testing of Prefilled Syringes 23
6.12 Customization of Prefilled Syringes 23
6.13 Self-injection Improvements 24
6.14 Patient-centric Focus for CMOs 24

7 Appendix 25
7.1 Market Definitions 25
7.2 Abbreviations 25
7.3 Bibliography 25
7.4 Research Methodology 26
7.4.1 Coverage 26
7.4.2 Secondary Research 27
7.4.3 Primary Research 27
7.4.4 Expert Panel Validation 27
7.5 Contact Us 28
7.6 Disclaimer 28
.

» Read More...

Generic Growth Strategies Market - Driven By Impending Patent Cliff, Declining R&D Productivity And Government Initiatives To Reduce Healthcare Costs


GBI Research, the leading business intelligence provider, has released its latest research, Generic Growth Strategies Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs. The report provides a comprehensive overview of the generic drugs market in the US, the top five countries in the European Union (EU, covering the UK, France, Germany, Spain and Italy) and Japan. 

The report focuses on the detailed analysis of major strategies implemented by the top 10 generic companies in the generic drugs market along with company portfolios and strategic analysis. The report gives detail on the current landscape and changes that have structured the generic drugs market. The report also contains an impact analysis of the regulatory landscape in the major geographies pertaining to the generic drugs market. The report also provides in-depth analysis of the unmet needs, drivers and barriers that affect the global generics market. 
     
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.
 
The global generics market generated revenues of approximately $162 billion with a growth of 9.3% in 2011, representing about 19% of generic market share in the international pharmaceutical market. The generic pharmaceutical industry is significantly fragmented; the top 10 pharmaceutical companies accounted for 26% of global generics sales by value in 2011. The US has very high levels of generic utilization, with nearly 80% of prescriptions dispensed being generics. 
 
The pharmaceutical industry will experience major patent expiries during 20132020, of which 2014 to 2017 are expected to be peak years, with the loss of patents for drugs whose sales were worth more than $76 billion during 2011. By 2015, branded products with sales of up to $135 billion will go off-patent, giving generic pharmaceutical companies immense opportunities to capitalize on the market. Along with generic drugs, pharmaceutical companies will also have the opportunity to develop biosimilars, as biologics with 2011 sales of approximately $64 billion will go off-patent over the next five years.
 

Scope
  • Detailed study of generic growth strategies with special emphasis on strategies which help in combating intensive competition.
  • Analysis of the major strategies adopted by companies looking to expand geographical reach.
  • Analysis of the generic pharmaceutical market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Key drivers and barriers that have a significant impact on the market.
  • Competitive benchmarking of leading companies. Key companies studied in this report are Teva, Sandoz, Mylan, Watson, Actavis, Hospira, Sanofi, Daiichi Sankyo, Aspen and STADA.
Reasons to buy
  • Build understanding of the key generic growth strategies in place and the trends in the market.
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutics market segments poised for strong growth.
  • Create a more tailored country strategy through the understanding of key drivers and barriers in the global generics market.
  • Optimize your R&D pipeline through the identification and understanding of the key strategy for your drug. 
  • Identify the key players best positioned to capitalize on their products through the effective management of their patented products.
  • Develop effective business strategies related to generic drugs through the analytical insight gained from case studies covering different strategies in the market.
Table of Contents

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 10

2 Generic Growth Strategies - Introduction 11
3 Generic Growth Strategies - Market Overview 12
3.1 Overview of the Generics Market 12
3.1.1 Leading Generics Companies 12
3.1.2 Generics Market Share 14
3.2 Drivers and Restraints 15
3.2.1 Drivers 16
3.2.2 Restraints 21

4 Generic Growth Strategies - Regulatory Landscape 23
4.1 The US 23
4.1.1 Hatch-Waxman Act and ANDA 23
4.1.2 Shortening Market Exclusivity of Biopharmaceuticals and Impact on Generics 25
4.1.3 Pay-For-Delay Ban to be Detrimental to Innovators as Well as Generics 25
4.1.4 Cost-sharing of Generic Drugs 25
4.1.5 Impact of Supplemental Examination Provision of Patent Reform Act on Generics 26
4.1.6 Biologics Price Competition and Innovation Act Falls Short 26
4.2 Europe 28
4.2.1 Generic Penetration 28
4.2.2 Generic Substitution 29
4.2.3 Pricing and Reimbursement 29
4.2.4 Marketing Authorization for Generics 29
4.2.5 Generic Landscape in Leading European Markets 29
4.2.6 Common European Union Patent System 31
4.2.7 Tendering 32
4.2.8 Regulatory Landscape for Biosimilars 32
4.2.9 The Future of Biosimilars is Advancing Along a Path Smoothened by European Groundwork 32
4.3 Japan 33
4.3.1 Generics 33
4.3.2 Biosimilar 34

5 Generic Growth Strategies - Major Strategies 35
5.1 Authorized Generics 35
5.1.1 Case Study 37
5.2 Mergers and Acquisitions 37
5.2.1 Vertical Integration 39
5.2.2 Therapeutic Expansion - Biosimilars 39
5.3 Outsourcing 40
5.3.1 Outsourcing Opportunities in Biosimilars 40
5.3.2 Outsourcing is Also a Source of Income for Generics Companies 40
5.4 Marketing Partnership 41
5.4.1 Case Studies 41
5.5 Paragraph IV Certifications 42
5.5.1 Case Studies 42
5.5.2 Example of a Paragraph IV Challenge That Did Not Work Out for a Generic 42
5.6 R&D Strategies Employed by Key Players in the Generics Market 43
5.6.1 Super Generics 43
5.6.2 Biosimilars 44
5.7 Increasing Awareness and Acceptance 46

6 Generic Growth Strategies - Competitive Landscape 47
6.1 Teva Pharmaceutical Industries Limited 47
6.1.1 Overview 47
6.1.2 Revenue Analysis 47
6.1.3 Therapeutic Focus 48
6.1.4 Geographic Focus 48
6.1.5 Generic Growth Strategies 48
6.1.6 SWOT 51
6.2 Sandoz 52
6.2.1 Overview 52
6.2.2 Revenue Analysis 52
6.2.3 Therapeutic Focus 52
6.2.4 Geographic Focus 52
6.2.5 Generic Growth Strategies 53
6.2.6 SWOT 54
6.3 Mylan 55
6.3.1 Overview 55
6.3.2 Revenue Analysis 55
6.3.3 Therapeutic Focus 55
6.3.4 Geographic Focus 55
6.3.5 Generic Growth Strategies 57
6.3.6 SWOT 58
6.4 Watson 59
6.4.1 Overview 59
6.4.2 Revenue Analysis 59
6.4.3 Therapeutic Focus 59
6.4.4 Geographic Focus 59
6.4.5 Generic Growth Strategies 60
6.4.6 SWOT 61
6.5 Actavis 62
6.5.1 Overview 62
6.5.2 Revenue Analysis 62
6.5.3 Therapeutic Focus 62
6.5.4 Geographic Focus 62
6.5.5 Generic Growth Strategies 62
6.5.6 SWOT 63
6.6 Hospira 64
6.6.1 Overview 64
6.6.2 Revenue Analysis 64
6.6.3 Therapeutic Focus 64
6.6.4 Geographic Focus 64
6.6.5 Generic Growth Strategies 65
6.6.6 SWOT 66
6.7 Sanofi 67
6.7.1 Overview 67
6.7.2 Revenue Analysis 67
6.7.3 Geographic Focus 67
6.7.4 Generic Growth Strategies 67
6.7.5 SWOT 68
6.8 Daiichi Sankyo 68
6.8.1 Overview 68
6.8.2 Revenue Analysis 68
6.8.3 Geographic Focus 68
6.8.4 Generic Growth Strategies 68
6.8.5 SWOT 69
6.9 Aspen 69
6.9.1 Overview 69
6.9.2 Revenue Analysis 69
6.9.3 Geographic Focus 69
6.9.4 Generic Growth Strategies 70
6.9.5 SWOT 70
6.10 STADA 71
6.10.1 Overview 71
6.10.2 Revenue Analysis 71
6.10.3 Therapeutic Focus 71
6.10.4 Geographic Focus 71
6.10.5 Generic Growth Strategies 72
6.10.6 SWOT 72

7 Generic Growth Strategies - Conclusion 73
8 Generic Growth Strategies - Appendix 74
8.1 Market Definitions 74
8.2 Abbreviations 74
8.3 Bibliography 75
8.4 Research Methodology 77
8.4.1 Coverage 77
8.4.2 Secondary Research 77
8.4.3 Primary Research 78
8.4.4 Expert Panel Validation 78
8.5 Contact Us 78
8.6 Disclaimer 78
.

» Read More...

Stem Cell Therapy Market In Asia-Pacific To 2018 - Commercialization Supported By Favorable Government Policies, Strong Pipeline And Increased Licensing Activity


GBI Research, the leading business intelligence provider, has released its latest research Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

    
 
GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals JR-031 (2014) in Japan and FCB Pharmicells Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. 

Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

 
Scope
  • Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore
  • In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. 
  • Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. 
  • Key drivers and restraints that have a significant impact on the market.
  • Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost
  • Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.
Reasons to buy
  • Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth 
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
  • Develop key strategic initiatives by studying the key strategies of top competitors
  • Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety
Browse : Browse Report : Stem Cell Therapy Market 2018

Table of Contents
 
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10


2 Stem Cell Therapy Market in Asia-Pacific to 2018 - Introduction 13

3 Stem Cell Therapy Market in Asia-Pacific to 2018 - Overview 14

3.1 Introduction 14
3.2 Market Characterization and Forecasts - Overview 15
3.2.1 Revenue Forecasts 15
3.2.2 Cost of Therapy 16
3.2.3 Allogeneic and Autologous Share 17
3.2.4 Stem Cell Therapy Patient Pool 18
3.3 Drivers and Barriers 19
3.3.1 Drivers 20
3.3.2 Barriers 20
4 Stem Cell Therapy Market in Asia-Pacific to 2018 - India 21
4.1 Introduction 21
4.2 Regulatory Landscape 21
4.3 Market Characterization and Forecasts - Overview 22
4.3.1 Revenue Forecasts 22
4.3.2 Cost of Therapy 23
4.3.3 Stem Cell Patient Pool 23
4.4 CABG Market Characterization and Forecasts 24
4.4.1 Introduction 24
4.4.2 Revenue Forecasts 24
4.4.3 Cost of Therapy 25
4.4.4 Stem Cell Patient Pool 26
4.5 Type 2 DM Market Characterization and Forecasts 27
4.5.1 Introduction 27
4.5.2 Revenue Forecasts 28
4.5.3 Cost of Therapy 29
4.5.4 Stem Cell Patient Pool 30
4.6 LSCT Market Characterization and Forecasts 31
4.6.1 Introduction 31
4.6.2 Revenue Forecasts 31
4.6.3 Cost of Therapy 32
4.6.4 Stem Cell Patient Pool 33

5 Stem Cell Therapy Market in Asia-Pacific to 2018 - China 34
5.1 Introduction 34
5.2 Regulatory Landscape 34
5.3 Market Characterization and Forecasts - Overview 35
5.3.1 Type 1 DM Market Characterization and Forecasts 35

6 Stem Cell Therapy Market in Asia-Pacific to 2018 - Japan 39
6.1 Introduction 39
6.2 Regulatory Landscape 39
6.3 Steroid Refractory aGvHD Market Characterization and Forecasts 41
6.3.1 Overview 41
6.3.2 Revenue Forecasts 42
6.3.3 Cost of Therapy 43
6.3.4 Stem Cell Patient Pool 44

7 Stem Cell Therapy Market in Asia-Pacific to 2018 - Singapore 45
7.1 Introduction 45
7.2 Regulatory Landscape 45
7.2.1 Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning (June 2002) 46
7.2.2 Human Tissue Research (November 2002) 47
7.2.3 Research Involving Human Subjects (November 2004) 48
7.2.4 Genetic Testing and Genetic Research (November 2005) 49
7.2.5 Personal Information in Biomedical Research (May 2007) 50
7.2.6 Donation of Human Eggs for Research (November 2008) 50
7.2.7 Human-Animal Combinations in Stem Cell Research (September 2010) 50

8 Stem Cell Therapy Market in Asia-Pacific to 2018 - South Korea 51
8.1 Introduction 51
8.2 Regulatory Landscape 51
8.3 Market Characterization and Forecasts - Overview 53
8.3.1 Revenue Forecasts 53
8.3.2 Cost of Therapy 55
8.3.3 Stem Cell Patient Pool 56
8.4 Cupistem Market Characterization and Forecasts 57
8.4.1 Overview 57
8.4.2 Revenue Forecasts 58
8.4.3 Cost of Therapy 59
8.4.4 Stem Cell Patient Pool 60
8.5 HCG-AMI Market Characterization and Forecasts 61
8.5.1 Overview 61
8.5.2 Revenue Forecasts 62
8.5.3 Cost of Therapy 63
8.5.4 Stem Cell Patient Pool 64
8.6 Cartistem Market Characterization and Forecasts 65
8.6.1 Overview 65
8.6.2 Revenue Forecasts 66
8.6.3 Cost of Therapy 67
8.6.4 Stem Cell Patient Pool 68
8.7 CCG Market Characterization and Forecasts 69
8.7.1 Overview 69
8.7.2 Revenue Forecasts 69
8.7.3 Cost of Therapy 70
8.7.4 Stem Cell Patient Pool 71

9 Stem Cell Therapy Market in Asia-Pacific to 2018 - Pipeline Analysis 72
9.1 Pipeline Analysis by Phase 72
9.2 Pipeline Analysis by Sponsors/Collaborators 73
9.3 Pipeline Analysis by Country 74
9.3.1 India Stem Cell R&D Pipeline 75
9.3.2 China Stem Cell R&D Pipeline 77
9.3.3 Japan Stem Cell R&D Pipeline 81
9.3.4 Singapore Stem Cell R&D Pipeline 85
9.3.5 South Korea Stem Cell R&D Pipeline 86
9.3.6 Product Profiles of Promising Molecules 88
9.3.7 Product Profiles of Marketed Products 89

10 Stem Cell Therapy Market in Asia-Pacific to 2018 - Competitive Landscape 91
10.1 Stempeutics Research 91
10.1.1 Overview 91
10.1.2 Product Pipeline 92
10.2 Reliance Life Sciences 93
10.2.1 Overview 93
10.2.2 Product Pipeline 93
10.3 International Stem Cell Services 94
10.3.1 Overview 94
10.3.2 Product Pipeline 94
10.4 Shenzhen Beike Biotechnology 95
10.4.1 Overview 95
10.4.2 Product Pipeline 95
10.5 JCR Pharmaceuticals 96
10.5.1 Overview 96
10.5.2 Product Pipeline 96
10.6 ES Cells International (Subsidiary of BioTime, Inc) 97
10.6.1 Overview 97
10.6.2 Product Pipeline 97
10.7 Stem Cell Technologies i 98
10.7.1 Overview 98
10.7.2 Product Pipeline 98
10.8 Pharmicell 99
10.8.1 Overview 99
10.8.2 Product Pipeline 99
10.9 Medipost 100
10.9.1 Overview 100
10.9.2 Product Pipeline 100

11 Stem Cell Therapy Market in Asia-Pacific to 2018 - Strategic Consolidations 101
11.1 Overview 101
11.2 M&A Deals 102
11.2.1 RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m - October 28, 2011 102
11.2.2 BioTime Acquired ES Cell International - May 3, 2010 102
11.2.3 BCCL Acquires Stake in Life Cell - May 1, 2007 102
11.3 Licensing Deals 102
11.3.1 RNL BIO Forms Joint Venture to Develop Stem Cell Therapy - September 29, 2011 102
11.3.2 Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR - January 4, 2011 102
11.3.3 Cipla Enters into Co-Marketing Agreement with Stempeutics - April 27, 2010 102
11.3.4 Teijin Enters into Licensing Agreement with SanBio - March 2, 2010 102
11.3.5 Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma - September 9, 2009 103
11.3.6 Merck Signs a Licensing Agreement with Japan Tobacco - September 25, 2008 103
11.3.7 ES Cell Enters into Licensing Agreement with ITI Life Sciences - January 31, 2007 103
11.4 Co-Development Deals 103
11.4.1 JCR Pharma Enters into Co-Development Agreement with MediPal - September 13, 2011 103
11.4.2 Athersys Enters into Co-Development Agreement with Pfizer - December 21, 2009 103
11.4.3 Genzyme Enters into Agreement with Osiris Therapeutics - November 4, 2008 104
11.4.4 JCR Pharma Enters into Co-Development Agreement with Mochida Pharma - December 21, 2007 104

12 Stem Cell Therapy Market in Asia-Pacific to 2018 - Appendix 105
12.1 Market Definitions 105
12.2 Abbreviations 105
12.3 Bibliography 107
12.4 Research Methodology 108
12.4.1 Coverage 108
12.4.2 Secondary Research 108
12.4.3 Primary Research 109
12.5 Therapeutic Landscape 109
12.5.2 Market Size by Geography 111
12.6 Geographical Landscape 112
12.7 Pipeline Analysis 112
12.8 Competitive Landscape 112
12.8.1 Expert Panel Validation 112
12.9 Contact Us 112
12.10 Disclaimer 112
.

» Read More...

Mobile Health Market (MHealth) - Enhancing Healthcare And Improving Clinical Outcomes


GBI Research, the leading business intelligence provider, has released its latest research report: Mobile Health (mHealth) Enhancing Healthcare and Improving Clinical Outcomes. The report examines how mHealth, which is the facilitation of health-related information through mobile-enabled technologies, has been applied by the pharmaceutical industry in drug development and by healthcare providers in the developed and emerging economies to improve healthcare services and treatment outcomes.
 
It looks in detail at the ways in which the pharmaceutical industry has utilized mobile technologies in patient recruitment, compliance and retention of clinical trials, its role in marketing and consumer education and the important developments in drug authentication and post-market surveillance.

    
 
The report investigates how the healthcare system has migrated from a paper-based system to an electronic one and the innovative ways in which this can be used enhance the flow of medical information. It assesses the growing use of mobile health apps as reference and diagnostic tools to support decision-making and highlights how mHealth can improve communication between patients and healthcare providers; empowering patients to take a more active role in their health and improving the continuum of healthcare from the clinic to the home.
 
Lastly, the report examines how mHealth programs in the emerging economies and the developed world can help to bridge the gap within fragmented under-resourced healthcare systems. It highlights how technologies devised for the developed countries are not always suitable for the developing countries and the need for local communities to devise mHealth solutions to address local issues such as infectious diseases (dengue fever, AIDS/HIV and tuberculosis) and high infant and maternal mortality rates.

Browse Report : Mobile Health Market
 
The report is built using information from primary and secondary research including interviews with experts in the field.
 
GBI Researchs analysis concludes that mHealth has huge potential to bridge the gap within existing healthcare systems but highlights the significant differences in the rate of adoption of mHealth in the developed world compared to the developing countries due to their existing infrastructures and differing doctor-centric and patient centric approaches to healthcare.
 
The mHealth alliance has identified five critical areas that need to be addressed if mHealth is to become main stream in global health: evidence building, standards and interoperability, sustainable financing, capacity building and policy. This will only be achieved if all stakeholders (patients, healthcare professionals and providers, pharmaceutical industry, mobile network operators and governments) work together to determine the ways in which mHealth can add value and provide significant advantages over traditional routes of healthcare communication.
 
Scope
  • Detailed analysis of how the pharmaceutical industry is applying mHealth in clinical trials, marketing and supply chain management
  • Assessment of the e-patient engagement strategies that healthcare providers (medical professional, clinicians pharmacists and health insurers) are adopting to improve communication with patients
  • Exploration of the role of mobile health tools in supporting physicians decision-making and prescribable apps to support patient healthcare requirements
  • Explorations of the key challenges facing the adoption of mHealth in the developed world and emerging economies
  • Case studies of mHealth programs and solutions in trial recruitment, supply chain management, decision support tools, education and awareness programs and many more
Reasons to buy
  • Identify key stakeholders and the role they play in the development of mHealth solutions
  • Understand what mHealth services are available and how and where they are being utilized
  • Learn the barriers to implementation and how these may be overcome
  • Understand current thinking on innovative areas of mHealth and its application by the pharmaceutical industry
  • Identify potential opportunities for mHealth solutions by healthcare providers
  • Explore the current mHealth programs and assess the ways these may be translated in other areas of the world
Browse Report : Global Mobile Health Industry

Table of Contents
 
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 What is mHealth? 7
2.2 mHealth Aims 8
2.3 Stakeholder Groups Involved in the Funding and Provision of mHealth 9
2.4 Role of mHealth Technologies in the Pharmaceutical Industry 10
2.5 Key Market Segments in the mHealth Space 10
2.5.1 Mobile Health - Mobile Network Operators 10
2.5.2 Mobile Health - Pharmaceutical Industry 10
2.5.3 Mobile Health - Healthcare Professionals 11
2.5.4 Mobile Health - Healthcare Providers 11
2.5.5 Mobile Health - Consumers 11

3 mHealth in Drug Development 12
3.1 Introduction 12
3.2 Mobile Health in Pharmaceutical R&D 13
3.3 Patient Recruitment in Clinical Trials 14
3.3.1 Case Study: REMOTE (Pfizer) 14
3.3.2 Social Media 14
3.4 Patient Compliance and Retention in Clinical Trials 16
3.5 Safety Data Collection 17
3.6 Consumer Education 18
3.7 Mobile Medical Education 18
3.8 Drug Authentication 19
3.9 Post-market Surveillance 20
4 mHealth in Healthcare 21
4.1 Introduction 21
4.2 Electronic Personal Health Records 21
4.3 Electronic Health Records and Medical Records 22
4.3.1 Electronic Health Records and Observational Studies 22
4.4 Clinical Decision Support Systems 23
4.4.1 Case Study: Epocrates 23
4.5 Mobile Healthcare for Healthcare Providers 24
4.5.1 Prescribable Apps 25
4.5.2 Virtual Consultations 25
4.6 Recent Innovations in Medical Diagnostics 26
4.7 Barriers to mHealth Implementation 27
5 Transforming Healthcare in the Emerging Economies through mHealth 28
5.1 Introduction 28
5.2 Shortage of Medical Resources 29
5.3 Improving the Flow of Health Information 30
5.4 Role of the mHealth Alliance 31
5.5 mHealth Applications in the Emerging Economies 32
5.6 Disease Surveillance 33
5.7 Education and Awareness 35
5.7.1 Mobile Technology for Community Health 35
5.7.2 iTEACH 35
5.8 Healthcare Information Management Systems 37
5.9 Health Financing 38
5.10 Patient Monitoring and Support 38
5.11 Point-of-care Services 40
5.12 Barriers to mHealth Implementation in the Emerging Economies 42
5.13 Overall Conclusions 42
6 Appendix 43
6.1 Acronyms 43
6.2 Bibliography 44
6.3 Terminology 48
6.4 Methodology 48
6.4.1 Primary Research 48
6.4.2 Secondary Research 49
6.5 Contact Us 49
6.6 Disclaimer 49
.
Browse Report : http://www.businessresearchindustry.com/report/mobile-health-mhealth-enhancing-healthcare-and-improving-clinical-outcomes.htm

» Read More...

Spinal Surgery Devices Market To 2018 – New Entrants And Technological Advances To Intensify Competition In The Spinal Fusion Segment


GBI Researchs report, Spinal Surgery Devices Market to 2018 New Entrants and Technological Advances to Intensify Competition in the Spinal Fusion Segment provides key data, information and analysis on the global spinal surgery devices market. The report outlines the market landscape and competitive landscape and gives information on market trends for the spinal fusion devices segment and the spinal non-fusion devices segment.
    
The report provides comprehensive information on the key trends affecting these categories, and key analytical content on market dynamics. The report also reviews the competitive landscape and analyzes in detail the pipeline products in each segment. In addition, it reviews the details of important M&A deals that have taken place in the global spinal surgery devices market. 
 
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts
 
Scope
  • Key geographies of the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil
  • Information on market size for two spinal surgery devices market segments: spinal fusion and spinal non-fusion
  • Annualized market revenue data, forecasts to 2018 and company share data for 2011
  • Qualitative analysis of key market trends for the spinal surgery devices market
  • Information on the leading market players, the competitive landscape, and the leading technologies in the market

Reasons to buy
  • Develop business strategies by understanding the trends and developments driving the global spinal surgery devices market
  • Design and develop your product development, marketing and sales strategies
  • Exploit M&A opportunities by identifying market players with the most innovative pipelines
  • Develop market-entry and market-expansion strategies
  • Identify key players best positioned to take advantage of the emerging market opportunities
  • Exploit in-licensing and out-licensing opportunities by identifying products most likely to ensure a robust return
  • Identify, understand and capitalize on the next big thing in the spinal surgery devices market landscape
  • Make more informed business decisions from the insightful and in-depth analysis of the global spinal surgery devices market and the factors shaping it
Table of Contents
 
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 9
 
2 Introduction 10
 
3 Spinal Surgery Devices  - Overview 11
3.1 Spinal Fusion Devices 11
3.2 Spinal Non-Fusion Devices 11
 
4 Spinal Surgery Devices - Market Characterization 12
4.1 Global Spinal Surgery Devices Market, Revenue ($m), 2004-2011 12
4.2 Global Spinal Surgery Devices Market, Revenue ($m), 2011-2018 13
4.3 Global Spinal Surgery Devices Market, Key Company Share (%), 2011 14
4.4 Global Spinal Surgery Devices: Key Trends 15
4.4.1 Physician-Owned Distributorship Models Experience a Decline in the Spinal Surgery Market 15
4.4.2 Competition Expected to Increase as Companies Capitalize on Technological Advances in the Spinal Fusion Market 16
4.5 Global Spinal Surgery Devices: Market Dynamics 18
4.5.1 Market Drivers 18
4.5.2 Market Restraints 21
 
5 Global Spinal Surgery Devices Market - Segment Analysis and Forecasts 23
5.1 Global Spinal Fusion Devices Market, Revenue ($m), 2004-2011 23
5.2 Global Spinal Fusion Devices Market, Revenue ($m), 2011-2018 24
5.3 Global Spinal Fusion Devices: Market Dynamics 25
5.3.1 Market Drivers 25
5.3.2 Market Restraints 26
5.4 Global Spinal Non-Fusion Devices Market, Revenue ($m), 2004-2011 27
5.5 Global Spinal Non-Fusion Devices Market, Revenue ($m), 2011-2018 28
5.6 Global Spinal Non-Fusion Devices: Market Dynamics 29
5.6.1 Market Drivers 29
5.6.2 Market Restraints 31
 
6 Global Spinal Surgery Devices Market - Country Analysis and Forecasts 33
6.1 Spinal Surgery Devices Market: Cross-country Analysis 33
6.2 Historic and Forecast Revenue, By Country 35
6.2.1 Spinal Surgery Devices Market, US, Revenue ($m), 2004-2011 35
6.2.2 Spinal Surgery Devices Market, US, Revenue ($m), 2011-2018 36
6.2.3 Spinal Surgery Devices Market, Japan, Revenue ($m), 2004-2011 37
6.2.4 Spinal Surgery Devices Market, Japan, Revenue ($m), 2011-2018 38
6.2.5 Spinal Surgery Devices Market, Germany, Revenue ($m), 2004-2011 39
6.2.6 Spinal Surgery Devices Market, Germany, Revenue ($m), 2011-2018 40
6.2.7 Spinal Surgery Devices Market, China, Revenue ($m), 2004-2011 41
6.2.8 Spinal Surgery Devices Market, China, Revenue ($m), 2011-2018 42
6.2.9 Spinal Surgery Devices Market, UK, Revenue ($m), 2004-2011 43
6.2.10 Spinal Surgery Devices Market, UK, Revenue ($m), 2011-2018 44
6.2.11 Spinal Surgery Devices Market, Spain, Revenue ($m), 2004-2011 45
6.2.12 Spinal Surgery Devices Market, Spain, Revenue ($m), 2011-2018 46
6.2.13 Spinal Surgery Devices Market, France, Revenue ($m), 2004-2011 47
6.2.14 Spinal Surgery Devices Market, France, Revenue ($m), 2011-2018 48
6.2.15 Spinal Surgery Devices Market, Italy, Revenue ($m), 2004-2011 49
6.2.16 Spinal Surgery Devices Market, Italy, Revenue ($m), 2011-2018 50
6.2.17 Spinal Surgery Devices Market, Australia, Revenue ($m), 2004-2011 51
6.2.18 Spinal Surgery Devices Market, Australia, Revenue ($m), 2011-2018 52
6.2.19 Spinal Surgery Devices Market, Brazil, Revenue ($m), 2004-2011 53
6.2.20 Spinal Surgery Devices Market, Brazil, Revenue ($m), 2011-2018 54
6.2.21 Spinal Surgery Devices Market, Canada, Revenue ($m), 2004-2011 55
6.2.22 Spinal Surgery Devices Market, Canada, Revenue ($m), 2011-2018 56
6.2.23 Spinal Surgery Devices Market, India, Revenue ($m), 2004-2011 57
6.2.24 Spinal Surgery Devices Market, India, Revenue ($m), 2011-2018 58

 Browse Report : Spinal Surgery Devices Market

7 Global Spinal Surgery Devices Market - Competitive Assessment 59
7.1 Medtronic 60
7.1.1 Business Overview 60
7.1.2 Products Marketed 60
7.2 DePuy Synthes 61
7.2.1 Business Overview 61
7.2.2 Products Marketed 61
7.3 Stryker 62
7.3.1 Business Overview 62
7.3.2 Products Marketed 62
7.4 NuVasive 63
7.4.1 Business Overview 63
7.4.2 Products Marketed 63
7.5 Orthofix 64
7.5.1 Business Overview 64
7.5.2 Products Marketed 64
7.6 Zimmer Holdings 65
7.6.1 Business Overview 65
7.6.2 Products Marketed 65
7.7 Globus Medical 66
7.7.1 Business Overview 66
7.7.2 Products Marketed 66
7.8 Alphatec Holdings 67
7.8.1 Business Overview 67
7.8.2 Products Marketed 67
7.9 B. Braun Medical 68
7.9.1 Business Overview 68
7.9.2 Products Marketed 68
 
8 Global Spinal Surgery Devices Market - Product Pipeline Analysis 69
8.1 Spinal Fusion Devices: Product Pipeline 70
8.1.1 Spinal Fusion Devices: Profiles of Key Pipeline Products 70
8.1.2 Spinal Fusion Devices: List of Pipeline Products 74
8.2 Spinal Non-Fusion Devices: Product Pipelin 77
8.2.1 Spinal Non-Fusion Devices: Profiles of Key Pipeline Products 77
8.2.2 Spinal Non-Fusion Devices: List of Pipeline Products 82
 
9 Global Spinal Surgery Devices Market - Consolidation Landscape 85
9.1 Spinal Surgery Devices Market: Number of Deals and Deal Value, 2007-2011 85
9.2 Key Deals: 2007-2011 86
9.2.1 Globus Medical’s Acquisition of Facet Solutions 86
9.2.2 Alphatec Spine’s Acquisition of Scient'x Groupe 86
9.2.3 NuVasive’s Acquisition of Cervitech 87
9.2.4 Zimmer Holdings’ Acquisition of Abbott Spine from Abbott Labs 88
9.2.5 Regeneration Technologies’ Acquisition of Tutogen Medical 89
9.2.6 Medtronic’s Acquisition of Kyphon 90
 
10 Appendix 91
10.1 Definitions 91
10.1.1 Spinal Surgery Devices 91
10.2 Acronyms 92
10.3 Sources 93
10.4 Research Methodology 94
10.4.1 Secondary Research 94
10.4.2 Primary Research 95
10.4.3 Models 95
10.4.4 Forecasts 95
10.4.5 Expert Panels 96
10.5 Contact Us 96
10.6 Disclaimer 96
.

» Read More...

Research Report on China's Shipbuilding Industry, 2013-2017

Research Report on China's Shipbuilding Industry, 2013-2017

    

Shipbuilding industry is a heavy industry undertaking the design, construction, maintenance and testing of various military and civil ships and producing the ancillary equipment.

The shipbuilding industry is a modern comprehensive industry providing technical equipment for industries such as water transportation, marine development and national defense construction, which is also a labor, capital and technologyintensive industry. It plays a relatively strong leading role in the development of upstream and downstream industries such as mechanic & electronic, steel, chemical, shipping and marine resource exploration &am

Original Post Research Report on China's Shipbuilding Industry, 2013-2017 source Business Research Industry




» Read More...

Tele-Health Carts Market, Servers, And Monitoring Industry Shares, Strategies, And Forecasts, Worldwide 2018


WinterGreen Research announces that it has a new study on Tele-Health Carts, Servers, and Monitoring Market Shares and Forecasts, Worldwide, 2012-2018. The 2012 study has 366 pages, 111 tables and figures. Tele-health improves treatment of chronic disease, reduces cost of care delivery, lets baby boomers age gracefully in their homes. Tele monitoring is evolving more sophisticated ways of monitoring vital signs in the home, thus protecting people in a familiar, comfortable environment. The improvements in care delivery relate to leveraging large information sources that permit understanding what care works for what conditions.

Tele-health systems server markets are anticipated to grow because they represent a way to steer patients with a particular clinician to those most expert in treating that particular condition. Tele-health is not yet to the point where it is able to be used effectively to implement changes that represent significant improvements in overall healthcare delivery, they are largely confined to being used in the treatment of chronic conditions.

The aim of tele-health systems that will grow markets significantly is if the tele-health is used to prevent the onset of chronic conditions of CHF and diabetes through interventional medicine, wellness programs, and simply intelligent nutrition and exercise programs implementation. Is this the task of the hospitals? Or, are well ness programs meant to be implemented elsewhere? In any case, tele-health represents the delivery mechanism for the programs.

Statins have a warning label that indicates that patients who take these drugs risk mental deterioration and diabetes. Is this what we want for our people? Or are there wellness programs that provide alternatives. These are issues confronting hospitals, physicians, clinicians, big pharma, and patients everywhere. We are all patients; the task is to figure out good tele-health systems that work to implement wellness programs before the onset of chronic conditions.

Under this scenario, the local physician and specialist becomes the expert in ordering the correct diagnostic tests, not just any test they can think of, but a proper test that is recommended by the expert systems and by the expert clinician. In this manner the out of control testing costs in the US can be controlled. There will need to be some law changes, there will need to be some adoption of protections for the expert doctors, but when decisions are backed by standards of care instantiated as tele health servers we begin to have a rational, very effective health care delivery system.

Browse Report : Telehealth systems server market

Use of tele-health systems in the treatment of chronic conditions is important. 90% of the cost of care delivery is tied up in the treatment of chronic conditions. A large percentage of the tele-monitoring servers was sold in the U.S., where the VA system did home monitoring of 92,000 patients in 2012. Tele-health equipment shipments are anticipated to grow rapidly worldwide as efficiencies of scale are realized for monitoring and treating people with chronic conditions in a more standardized manner that addresses the particular combinations and clusters of conditions any one patient presents.

Tele-health systems rely on monitors with integrated connectivity. Systems use monitoring hubs with integrated cellular capability and carts that permit remote diagnosis for places where there is a shortage of good doctors and where people want second opinions from a trusted expert. A physician that sees hundreds of patients a week with a certain condition is more apt to render an accurate diagnosis and to provide effective treatment than a physician that only sees that condition once a year.

The only way to connect patients with a particular condition with a clinician expert in treating that condition is through telemedicine. Everyone knows that a surgeon who operates within a particular specialty every day is more expert than one who operates only once a year. The same is true across the board for all specialties.

Systems like the Bosch health management programs with evidence-based guidelines are great in this context. These evidence based systems can be used to keep physicians and clinicians focused on the most significant part of the condition being treated.

IBM Watson is similarly great in the context of connecting expert clinicians with patients presenting a certain combination of symptoms. This type of care delivery represents significant change, but it is change for the better, it is lower cost care delivery with higher quality of care. Watson or competing computing systems have the potential to be incredibly useful in this context. Because Watson and other cognitive computing systems can recognize clusters of symptoms in a particular patient, these types of systems are potentially useful in guiding patients to the care delivery clinician that is most likely to be able to recognize the best treatment and to provide the recommendation ot other clinicians as to what will be the highest level of effective care for the least cost.

The aim of tele-monitoring is to improve patient compliance with standards of care known to support improved outcomes for patients with chronic conditions. Tele-monitoring is one way to improve patient compliance, but there are other ways to achieve that as well.

Tele-monitoring increases patient compliance. The aim is to improve the delivery of healthcare to clients by monitoring vital signs to detect changes in patient condition that may indicate the onset of a more serious event, much as nurses in the hospital monitor patient vital signs.

According to Susan Eustis, the principal author of the study, "The advantage of telemonitoring is that it increases patient compliance. It brings expert medicine into the home and attempts to present it in manner patients can hear. The aim is to improve the delivery of healthcare to clients by performing medical exams remotely and monitoring vital signs to detect changes in patient condition that may indicate the onset of a more serious event, much as nurses in the hospital monitor patient vital signs for the purpose of permitting sophisticated care delivery."

Tele-health equipment units decrease the cost of care delivery while improving the quality of care and the quality of lifestyle available to patients. They have been widely adopted and extremely successful in use by the veterans administration in the US and by CMS Medicare and Medicaid. Use is anticipated to be extended to a wide variety of care delivery organizations based on this base of installed systems. Healthcare delivery is an increasing concern worldwide. Markets for the carts and associated servers segment of the market at $98 million in the first three quarters of 2012 are anticipated to reach$1.4 billion by 2018.

» Read More...

Global Cloud-based VDI Market 2012-2016

Global Cloud-based VDI Market 2012-2016


    

TechNavio's analysts forecast the Global Cloud-based VDI market to grow at a CAGR of 30.6 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing need to reduce desktop infrastructure costs. The Global Cloud-based VDI market has also been witnessing the increasing use of handheld devices. However, the need for high initial capital investment could pose a challenge to the growth of this market.

TechNavio's report, the Global Cloud-based VDI market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the Global Cloud-based VDI market landscape and its growth prospects in the co

Original Post Global Cloud-based VDI Market 2012-2016 source Business Research Industry

» Read More...

Global Nitrogen Oxide (NOx) Control Equipment in Power Plants Market 2011-2015

Global Nitrogen Oxide (NOx) Control Equipment in Power Plants Market 2011-2015


    

TechNavio's analysts forecast the Global NOx Control Equipment in Power Plants market to grow at a CAGR of 5.26 percent over the period 2011-2015. One of the key factors contributing to this market growth is the strict environmental regulations. The Global NOx Control Equipment in Power Plants market has also been witnessing the increasing replacement of old equipment. However, the maturity of this market in developed nations could pose a challenge to the growth of this market.

TechNavio's report, Global Nitrogen Oxide (NOx) Control Equipment in Power Plants Market 2011-2015, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also c

Original Post Global Nitrogen Oxide (NOx) Control Equipment in Power Plants Market 2011-2015 source Business Research Industry





» Read More...

Syria Oil Markets, 2012

Syria Oil Markets, 2012


    

Syria Oil Markets, 2012


Summary


This profile is the essential source for top-level energy industry data and information. The report provides an overview of each of the key sub-segments of the energy industry in Syria. It details the market structure, regulatory environment, infrastructure and provides historical and forecasted statistics relating to the supply/demand balance for each of the key sub-segments. It also provides information relating to the crude oil assets (oil fields, refineries, pipelines and storage terminals) in Syria. The report compares the investment environment in Syria with other countries in the region. The profiles of the major compani

Original Post Syria Oil Markets, 2012 source Business Research Industry






» Read More...

Global Neurovascular Intervention Devices Market 2011-2015

Global Neurovascular Intervention Devices Market 2011-2015


    

TechNavio's analysts forecast the Global Neurovascular Intervention Devices market to grow at a CAGR of 11.25 percent over the period 2011-2015 One of the key factors contributing to this market growth is the huge patient population with various neurological disorders. The Global Neurovascular Intervention Devices market has also been witnessing the trend of an increase in mergers and acquisitions. However, the high cost of neurovascular intervention treatment could pose a challenge to the growth of this market.

TechNavio's report, the Global Neurovascular Intervention Devices Market 2011-2015, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC

Original Post Global Neurovascular Intervention Devices Market 2011-2015 source Business Research Industry




» Read More...

China Vitamin C Industry 2012 Market Research Report

China Vitamin C Industry 2012 Market Research Report

    


2012 Market Research Report on China Vitamin C Industry was professional and depth research report on China Vitamin C industry.

The report firstly introduced Vitamin C basic information included Vitamin C definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Vitamin C industry policy and plan, Vitamin C product specification, manufacturing process, product cost structure etc. then statistics China key manufacturers Vitamin C capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Vitamin C produ

Original Post China Vitamin C Industry 2012 Market Research Report source Business Research Industry




» Read More...

Mining Equipment Market in China 2011-2015

Mining Equipment Market in China 2011-2015

    

TechNavio's analysts forecast the Mining Equipment market in China to grow at a CAGR of 14.28 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing demand from the Coal Mining industry. The Mining Equipment market in China has also been witnessing the technological advancements in mining equipment. However, the need for high initial investment could pose a challenge to the growth of this market.

TechNavio's report, the Mining Equipment Market in China 2011-2015, has been prepared based on an in-depth market analysis with inputs from industry experts. The report focuses on China; it also covers the Mining Equipment market landscape and its growth prospects in the coming years. The

Original Post Mining Equipment Market in China 2011-2015 source Business Research Industry




» Read More...

Asia-Pacific Anesthesia and Respiratory Devices Market Outlook to 2018

Asia-Pacific Anesthesia and Respiratory Devices Market Outlook to 2018 - Respiratory Devices, Respiratory Measurement Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others

    
Summary

GlobalDatas new report, Asia-Pacific Anesthesia and Respiratory Devices Market Outlook to 2018 Respiratory Devices, Respiratory Measurement Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others provides key market data on the Asia Pacific Anesthesia and Respiratory Devices market Japan, China, India, and Australia. The report provides value (USD million) data for all the market categories Respiratory

Original Post Asia-Pacific Anesthesia and Respiratory Devices Market Outlook to 2018 - Respiratory Devices, Respiratory Measurement Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others source Business Research Industry




» Read More...

China Vitamin B5 Industry 2012 Market Research Report

  

2012 Market Research Report on China Vitamin B5 Industry was professional and depth research report on China Vitamin B5 industry. 

The report firstly introduced Vitamin B5 basic information included Vitamin B5 definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Vitamin B5 industry policy and plan, Vitamin B5 product specification, manufacturing process, product cost structure etc. then statistics China key manufacturers Vitamin B5 capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Vitamin 

» Read More...

Belgium Diagnostic Imaging Market Outlook to 2018

Belgium Diagnostic Imaging Market Outlook to 2018 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others

    

Belgium Diagnostic Imaging Market Outlook to 2018 Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others

Summary

GlobalDatas new report, Belgium Diagnostic Imaging Market Outlook to 2018 Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others provides key market data on the Belgium Diagnostic Imaging market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within 10 market categories Angio Suites, Bone Densitometers, C-Arms, Comput

Original Post Belgium Diagnostic Imaging Market Outlook to 2018 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others source Business Research Industry






» Read More...

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012

    

Summary

GlobalData's clinical trial report, Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012" provides data on the Focal Segmental Glomerulosclerosis (FSGS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Focal Segmental Glomerulosclerosis (FSGS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Focal Segmental Glomerulosclerosis (FSGS). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations 

  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy
  • Understand the dynamics of a particular indication in a condensed manner

  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

  • Obtain discontinued trial listing for trials across the globe

  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Original Post Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 source Business Research Industry






» Read More...

Search This Blog

About Me

My photo

The dedicated team of researchers and analysts at Business Research Industry into the Advantage of Knowledge for your company. Data becomes knowledge through the application of Dolcera's optimization process as follows.

Archives

Business Research Industry. Powered by Blogger.